CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity

Autor: JM Doehn, Christoph Tabeling, Elena Madlung, Leif G. Hanitsch, Alexander Uhrig, Rajan Somasundaram, Kathrin Heim, Jacopo Saccomanno, Eva Pappe, Ralf-Harto Hübner, Martin Witzenrath, Christian Meisel, Victor M. Corman, Miriam Stegemann, Sascha Treskatsch, Florian Kurth, Norbert Suttorp, Christoph Ruwwe-Glösenkamp, Leif E. Sander, Claudia Spies, Horst von Bernuth, Frieder Gabriel, Jörg Hofmann, Robert Biesen, Holger Müller-Redetzky, Christian Drosten
Rok vydání: 2021
Předmět:
Zdroj: Infection
ISSN: 1439-0973
0300-8126
DOI: 10.1007/s15010-021-01606-9
Popis: Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Type I interferons are important in the defense of viral infections. Recently, neutralizing IgG auto-antibodies against type I interferons were found in patients with severe COVID-19 infection. Here, we analyzed expression of CD169/SIGLEC1, a well described downstream molecule in interferon signaling, and found increased monocytic CD169/SIGLEC1 expression levels in patients with mild, acute COVID-19, compared to patients with severe disease. We recommend further clinical studies to evaluate the value of CD169/SIGLEC1 expression in patients with COVID-19 with or without auto-antibodies against type I interferons.
Databáze: OpenAIRE
Externí odkaz: